What is NDC 67184-0530?

67184-0530 is the product NDC for Bortezomib, Bortezomib 3.5 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by Qilu Pharmaceutical Co., Ltd..

Qilu Pharmaceutical Co., Ltd., NDC labeler code 67184. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Bortezomib?

29 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Bortezomib NDC 67184-0530 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)67184-0530Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67184-0530Add the package segment from the table below.

Product information

Brand name (proprietary): Bortezomib
Generic name (nonproprietary): bortezomib
Active ingredients: Bortezomib — 3.5 mg/1
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous, Subcutaneous
Labeler: Qilu Pharmaceutical Co., Ltd.NDC labeler code 67184
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210824
Marketing start: May 2, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Proteasome Inhibitors (Mechanism)
Identifiers: Product ID 67184-0530_7f2d7d7b-99b3-4b68-9bbd-89a8249c66a0SPL ID 7f2d7d7b-99b3-4b68-9bbd-89a8249c66a0SPL set ID aef02171-bf8a-43ad-b40c-7642623f9802RxCUI 402243UNII 69G8BD63PPUPC 0367184053018
Pharmacologic class: Proteasome Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

Product label

Current FDA label (SPL), effective May 9, 2022.

Indications (excerpt from the label)

Bortezomib for Injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for Injection is indicated for the treatment of adult patients with mantle cell lymphoma.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 67184-0530

What is NDC 67184-0530?: 67184-0530 is the product NDC for Bortezomib, Bortezomib 3.5 mg/1 injection, powder, lyophilized, for solution, listed with the FDA by Qilu Pharmaceutical Co., Ltd..
What drug is associated with this NDC?: Bortezomib.
What is the active ingredient?: Bortezomib.
Who is the labeler?: Qilu Pharmaceutical Co., Ltd., NDC labeler code 67184. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Bortezomib?: 29 other product NDCs are listed under this name. See all Bortezomib NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Bortezomib NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Bortezomib	Bortezomib 3.5 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Avenacy, LLC	83634-208	83634-0208-10
Bortezomib	Bortezomib 1 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Gland Pharma Limited	68083-650	68083-0650-01
Bortezomib	Bortezomib 2.5 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Gland Pharma Limited	68083-651	68083-0651-01
Bortezomib	Bortezomib 3.5 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Ningbo Shuangcheng Pharmaceutical Co., Ltd.	75007-501	75007-0501-3175007-0501-32
Bortezomib	Bortezomib 3.5 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Sagent Pharmaceuticals	25021-262	25021-0262-10
Bortezomib	Bortezomib 3.5 mg/3.5mL	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Somerset Therapeutics LLC	70069-836	70069-0836-01
Bortezomib	Bortezomib 3.5 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	NorthStar RxLLC	72603-270	72603-0270-01
Bortezomib	Bortezomib 3.5 mg/1.4mL	InjectionIntravenous, Subcutaneous	Shilpa Medicare Limited	63759-3032	63759-3032-01
Bortezomib	Bortezomib 3.5 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Camber Pharmaceuticals, Inc.	31722-303	31722-0303-31
Bortezomib	Bortezomib 3.5 mg/3.5mL	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Sintetica US LLC	83090-008	83090-0008-01

All 30 Bortezomib NDCs

Other NDCs under ANDA 210824

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210824
Product	Strength	Form · route	Labeler	Product NDC
Bortezomib	Bortezomib 3.5 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	Sagent Pharmaceuticals	25021-262
Bortezomib	Bortezomib 3.5 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous	BluePoint Laboratories	68001-540